Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

BACKGROUND: Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients. METHODS: A multicenter, single-arm, hypothesis-driven trial was planned, according to a phase 2 design, to study the effect o...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrone, Francesco, Piccirillo, Maria Carmela, Ascierto, Paolo Antonio, Salvarani, Carlo, Parrella, Roberto, Marata, Anna Maria, Popoli, Patrizia, Ferraris, Laurenzia, Marrocco-Trischitta, Massimiliano M., Ripamonti, Diego, Binda, Francesca, Bonfanti, Paolo, Squillace, Nicola, Castelli, Francesco, Muiesan, Maria Lorenza, Lichtner, Miriam, Calzetti, Carlo, Salerno, Nicola Duccio, Atripaldi, Luigi, Cascella, Marco, Costantini, Massimo, Dolci, Giovanni, Facciolongo, Nicola Cosimo, Fraganza, Fiorentino, Massari, Marco, Montesarchio, Vincenzo, Mussini, Cristina, Negri, Emanuele Alberto, Botti, Gerardo, Cardone, Claudia, Gargiulo, Piera, Gravina, Adriano, Schettino, Clorinda, Arenare, Laura, Chiodini, Paolo, Gallo, Ciro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576974/
https://www.ncbi.nlm.nih.gov/pubmed/33087150
http://dx.doi.org/10.1186/s12967-020-02573-9

Ejemplares similares

Ejemplares similares